Welcome to Doctar's comprehensive guide on Zejula (niraparib) dosage. If you or a loved one has been prescribed Zejula for ovarian cancer, understanding its dosage, administration, and potential implications is crucial for effective treatment and managing side effects. This article aims to provide detailed, factual information to help you navigate your treatment journey with confidence, always in consultation with your healthcare provider.

What is Zejula (Niraparib)?

Zejula is the brand name for the medication niraparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is a targeted therapy primarily used in the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. PARP inhibitors work by blocking PARP proteins, which are involved in repairing damaged DNA in cancer cells. By inhibiting PARP, Zejula prevents cancer cells from repairing their DNA, leading to cell death.

Indications for Zejula

Zejula is approved for several indications:

Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This includes patients regardless of their BRCA mutation status.
Treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status, defined by a deleterious or suspected deleterious BRCA mutation and/or genomic instability.

The specific indication for which Zejula is prescribed will influence the treatment plan and considerations, though the core dosage principles often remain similar for maintenance therapy.

Understanding Zejula Dosage

The dosage of Zejula is carefully determined by your oncologist based on your individual health profile, weight, and how your body responds to the medication. It's crucial to follow your doctor's instructions precisely and never adjust your dose without medical advice.

Initial Recommended Dosage

The standard initial recommended dose of Zejula for maintenance treatment of recurrent ovarian cancer is typically 300 mg (three 100 mg capsules) taken orally once daily. However, for certain patients, a lower starting dose may be recommended.

Weight-Based or Platelet Count-Based Starting Dose

In some cases, your doctor might initiate treatment with a lower dose based on specific factors:

Body Weight: If your body weight is less than 77 kg (approximately 170 lbs).
Baseline Platelet Count: If your baseline platelet count is less than 150,000/µL.

For patients meeting either of these criteria, the recommended starting dose may be 200 mg (two 100 mg capsules) taken orally once daily. This individualized approach helps manage potential side effects, particularly hematologic toxicities.

How to Take Zejula

Zejula should be taken once daily.
It can be taken with or without food. Taking it with food may help reduce nausea for some patients.
Try to take Zejula at approximately the same time each day to maintain consistent drug levels in your body.
Swallow the capsules whole. Do not chew, crush, or open them.

What if You Miss a Dose?

If you miss a dose of Zejula, do not take an extra dose to make up for the missed one. Simply take your next dose at the regularly scheduled time. If you vomit after taking a dose, do not take an additional dose. Continue with your next scheduled dose.

Dosage Adjustments and Management of Side Effects

One of the most critical aspects of Zejula treatment is the potential for dosage adjustments. Your doctor will monitor you closely for side effects, especially those related to bone marrow suppression (hematologic toxicities). These adjustments are made to help manage side effects while still providing therapeutic benefits.

Common Side Effects Requiring Monitoring

Your doctor will regularly monitor your blood counts, including complete blood counts (CBCs), especially during the first month of treatment and periodically thereafter. Common side effects that may necessitate dose modifications include:

Myelosuppression: This includes a decrease in red blood cells (anemia), white blood cells (neutropenia), and platelets (thrombocytopenia).
Non-hematologic toxicities: Such as fatigue, nausea, vomiting, abdominal pain, constipation, hypertension (high blood pressure), and headache.

Guidelines for Dose Reduction

If you experience certain side effects, your doctor may recommend reducing your Zejula dose. Typical dose reduction steps are:

From 300 mg once daily to 200 mg once daily.
From 200 mg once daily to 100 mg once daily.

If side effects persist or worsen even at the 100 mg dose, your doctor may temporarily interrupt treatment or discontinue Zejula permanently.

Example of Dosage Modification for Hematologic Toxicities

For severe hematologic toxicities (e.g., Grade 3 or 4 anemia, thrombocytopenia, or neutropenia):

First Occurrence: Your doctor may interrupt Zejula treatment until the toxicity resolves to Grade 1 or less. Upon resolution, treatment may be restarted at a reduced dose (e.g., from 300 mg to 200 mg, or from 200 mg to 100 mg).
Second Occurrence: If the same severe toxicity recurs, treatment will again be interrupted until resolution, and then resumed at a further reduced dose.
Third Occurrence: Further interruptions and dose reductions may be necessary.
Fourth Occurrence: If a Grade 3 or 4 hematologic toxicity recurs a fourth time despite prior dose reductions, Zejula may be permanently discontinued.

These are general guidelines, and your oncologist will make specific decisions based on your unique clinical situation.

Dosage in Specific Populations

Renal Impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Data for severe renal impairment or end-stage renal disease requiring hemodialysis are limited, and these patients should be monitored closely.
Hepatic Impairment: No dose adjustment is required for patients with mild hepatic impairment. For moderate hepatic impairment, a lower starting dose of 200 mg once daily is recommended. Zejula has not been studied in patients with severe hepatic impairment.
Elderly Patients: No specific dose adjustment is required for elderly patients (65 years or older), but they should be monitored closely for side effects.

Important Considerations While Taking Zejula

Potential Side Effects

Zejula can cause various side effects, ranging from mild to severe. It's important to be aware of these and report any new or worsening symptoms to your doctor.

Common Side Effects (may affect more than 1 in 10 people):

Nausea, vomiting, constipation, diarrhea, abdominal pain
Fatigue, weakness
Anemia, thrombocytopenia, neutropenia (low blood cell counts)
Headache, dizziness
Loss of appetite
Insomnia
High blood pressure (hypertension)
Palpitations
Mucositis (inflammation of the mucous membranes)
Rash
Back pain, joint pain

Serious Side Effects (less common but require immediate medical attention):

Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML): These are rare but serious blood cancers that have been reported in patients treated with PARP inhibitors, including Zejula. Symptoms may include extreme tiredness, fever, frequent infections, easy bruising or bleeding, and shortness of breath.
Bone Marrow Suppression: Severe low blood cell counts can lead to serious infections or bleeding.
High Blood Pressure and Heart Rate: Zejula can cause increases in blood pressure and heart rate. Your blood pressure and heart rate should be monitored regularly.
Posterior Reversible Encephalopathy Syndrome (PRES): This is a rare neurological disorder that can cause symptoms like headache, seizures, confusion, and vision changes.
Pneumonitis: Inflammation of the lungs.

Drug Interactions

Zejula is metabolized by an enzyme called carboxylesterase 1 (CES1). It is not a substrate for CYP enzymes, which reduces the potential for many common drug-drug interactions. However, it's still crucial to inform your doctor about all medications you are taking, including:

Prescription drugs
Over-the-counter medications
Vitamins
Herbal supplements

This allows your healthcare team to check for any potential interactions that could affect Zejula's efficacy or increase side effects.

Pregnancy and Breastfeeding

Pregnancy: Zejula can cause harm to an unborn baby. It is not recommended for use during pregnancy. Women of childbearing potential should use effective contraception during treatment and for 6 months after the last dose.
Breastfeeding: It is not known if Zejula passes into breast milk. Due to the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment with Zejula and for 1 month after the last dose.

Driving and Operating Machinery

Zejula can cause side effects such as fatigue, dizziness, or weakness, which may impair your ability to drive or operate machinery. Exercise caution until you know how Zejula affects you.

When to See a Doctor

Regular communication with your oncology team is vital throughout your Zejula treatment. You should contact your doctor immediately if you experience any of the following:

Signs of infection: Fever (especially over 100.4°F or 38°C), chills, sore throat, cough, burning with urination.
Unusual bleeding or bruising: Nosebleeds, bleeding gums, pinpoint red spots on the skin (petechiae), blood in urine or stools.
Severe fatigue or weakness: Especially if it's new or worsening.
Dizziness or fainting spells.
New or worsening shortness of breath.
Signs of high blood pressure: Severe headache, blurred vision, dizziness, confusion, chest pain, shortness of breath.
Any neurological symptoms: Severe headache, seizures, confusion, vision changes (potential signs of PRES).
Allergic reaction symptoms: Rash, itching, swelling of the face/tongue/throat, severe dizziness, trouble breathing.
Any other new or concerning symptoms.

Do not wait for your next appointment if you have urgent concerns. Your healthcare team is there to support you in managing your treatment effectively and safely.

FAQs About Zejula Dosage

Q1: How long will I need to take Zejula?

A: The duration of Zejula treatment varies depending on the specific indication, your response to the medication, and how well you tolerate it. For maintenance therapy, treatment typically continues until disease progression or unacceptable toxicity. Your doctor will discuss the expected duration with you.

Q2: Can I take Zejula if I have a BRCA mutation?

A: Yes, Zejula is approved for maintenance treatment of ovarian cancer regardless of BRCA mutation status. It is also approved for treatment of advanced ovarian cancer in patients with HRD-positive status, which includes those with a deleterious or suspected deleterious BRCA mutation.

Q3: What should I do if my blood counts are low?

A: Low blood counts (anemia, neutropenia, thrombocytopenia) are common side effects of Zejula. Your doctor will monitor your blood counts regularly. If they drop too low, your doctor may temporarily interrupt your treatment, reduce your dose, or prescribe supportive care (e.g., blood transfusions, growth factors) until your counts recover. It's important not to self-adjust your dose.

Q4: Does Zejula cause hair loss?

A: Hair loss (alopecia) is not a common side effect of Zejula, unlike some traditional chemotherapies. However, some patients may experience hair thinning or changes in hair texture.

Q5: Is Zejula a chemotherapy drug?

A: Zejula is a type of targeted therapy, specifically a PARP inhibitor. While it treats cancer, it works differently from traditional chemotherapy by targeting specific pathways involved in cancer cell growth and repair. This often results in a different side effect profile compared to conventional chemotherapy.

Q6: Can I drink alcohol while taking Zejula?

A: There are no specific contraindications for alcohol consumption with Zejula. However, alcohol can exacerbate certain side effects like nausea, fatigue, or liver issues. It's generally best to consume alcohol in moderation or avoid it entirely during cancer treatment. Discuss this with your doctor.

Q7: How is Zejula stored?

A: Store Zejula capsules at room temperature (68°F to 77°F or 20°C to 25°C), away from light and moisture. Keep it out of reach of children and pets.

Conclusion

Zejula (niraparib) represents a significant advancement in the treatment of ovarian cancer, offering a vital maintenance option for many patients. Understanding its correct dosage, potential side effects, and the importance of vigilant monitoring is paramount for achieving the best possible outcomes. Always remember that your oncology team is your primary resource for all questions and concerns regarding your treatment. Adherence to your prescribed dosage and open communication about any symptoms you experience are key to safely and effectively managing your cancer care journey.